The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Veracyte Inc (NASDAQ: VCYT) closed at $33.93 down -0.53% from its previous closing price of $34.11. In other words, the price has decreased by -$0.53 from its previous closing price. On the day, 1.32 million shares were traded. VCYT stock price reached its highest trading level at $34.89 during the session, while it also had its lowest trading level at $33.69.
Ratios:
For a deeper understanding of Veracyte Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.32 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 31.79. For the most recent quarter (mrq), Quick Ratio is recorded 5.10 and its Current Ratio is at 5.43. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Craig Hallum on March 20, 2025, initiated with a Buy rating and assigned the stock a target price of $45.
On December 05, 2024, Goldman Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $38 to $37. On November 15, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $50.Wolfe Research initiated its Outperform rating on November 15, 2024, with a $50 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 19 ’25 when ANN MCGUIRE bought 2,283 shares for $33.23 per share.
Stapley Marc sold 7,667 shares of VCYT for $233,133 on Sep 04 ’25. The Chief Executive Officer now owns 334,185 shares after completing the transaction at $30.41 per share. On Sep 04 ’25, another insider, MARC STAPLEY, who serves as the Director of the company, bought 7,667 shares for $30.62 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VCYT now has a Market Capitalization of 2685061376 and an Enterprise Value of 2399254016. As of this moment, Veracyte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 101.98, and their Forward P/E ratio for the next fiscal year is 23.32. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.40. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.57 while its Price-to-Book (P/B) ratio in mrq is 2.18. Its current Enterprise Value per Revenue stands at 5.008 whereas that against EBITDA is 37.618.
Stock Price History:
The Beta on a monthly basis for VCYT is 2.11, which has changed by 0.00592947 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, VCYT has reached a high of $47.32, while it has fallen to a 52-week low of $22.61. The 50-Day Moving Average of the stock is 19.64%, while the 200-Day Moving Average is calculated to be 3.49%.
Shares Statistics:
For the past three months, VCYT has traded an average of 1.46M shares per day and 1006470 over the past ten days. A total of 78.60M shares are outstanding, with a floating share count of 76.90M. Insiders hold about 2.25% of the company’s shares, while institutions hold 106.66% stake in the company. Shares short for VCYT as of 1756425600 were 8041793 with a Short Ratio of 5.50, compared to 1753920000 on 9075671. Therefore, it implies a Short% of Shares Outstanding of 8041793 and a Short% of Float of 11.399999.
Earnings Estimates
Current recommendations for the stock of the company come from 9.0 analysts. The consensus estimate for the next quarter is $0.37, with high estimates of $0.4 and low estimates of $0.35.
Analysts are recommending an EPS of between $1.47 and $1.38 for the fiscal current year, implying an average EPS of $1.43. EPS for the following year is $1.43, with 9.0 analysts recommending between $1.92 and $1.13.
Revenue Estimates
A total of 9 analysts believe the company’s revenue will be $124.62M this quarter.It ranges from a high estimate of $125.97M to a low estimate of $123.9M. As of the current estimate, Veracyte Inc’s year-ago sales were $115.86MFor the next quarter, 9 analysts are estimating revenue of $131.01M. There is a high estimate of $132.8M for the next quarter, whereas the lowest estimate is $128.8M.
A total of 10 analysts have provided revenue estimates for VCYT’s current fiscal year. The highest revenue estimate was $502.81M, while the lowest revenue estimate was $497.4M, resulting in an average revenue estimate of $500.29M. In the same quarter a year ago, actual revenue was $445.76MBased on 10 analysts’ estimates, the company’s revenue will be $549.29M in the next fiscal year. The high estimate is $560M and the low estimate is $540.64M.
